2026

>

Inhibitors in non-severe hemophilia A: a case report

>

Regarding plasma-derived von Willebrand factor concentrates: what about viral safety?

>

Endovascular intervention for intracranial aneurysm with dual anti platelet therapy in a patient with severe hemophilia A

>

Gene therapy with etranacogene dezaparvovec in haemophilia B: about the 1st patient infused in Spain

>

Avatrombopag: beyond efficacy: experience of a center

>

Prophylaxis in patients with moderate and mild haemophilia: experience from a single centre

>

Disease awareness in hemophilia: impact on therapeutic adherence and clinical outcomes

>

Spanish registry of real-world clinical practice in previously untreated or minimally treated patients with severe hemophilia A (RePUM-HA)

>

Indirect comparison of gene therapies in hemophilia A with use of generative artificial intelligence

>

Prophylaxis in hemophilia A: beyond PK – the potential role of procoagulant platelet in the hemostatic activity of rFVIII a